BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta after attending the MDA Clinical & Scientific Conference this week, saying that its AAVrh74 gene therapies have received "a lot of attention" in the areas of Duchenne Muscular Dystrophy, or DMD, and Limb Girdle Muscular Dystrophy, or LGMD. The analyst also notes that many of the sessions discussing novel potential gene therapies for DMD/LGMD have been "packed with physicians / scientists / industry reps", adding that manufacturing scale up for gene therapies has also been widely discussed.